It has been reported that the enrichment of CD8 T cells in CRC patients with MSI status is an important reason for their relatively higher sensitivity to immunotherapy with ICIs(Sui et al., 2021; Zou et al., 2021). This evidence concerns the gene CD8A and colorectal carcinoma.